Peptide Research Glossary: Terms, Classes & Testing

A CoA reports what analytical tests found on a specific batch, it does not certify safety, efficacy or suitability for any use beyond the stated research application. This glossary defines the core vocabulary used across peptide research: compound classes, receptor targets, analytical methods, batch documentation, handling formats and study-design terms. Researchers and prospective distributors can use it to distinguish compound classes by receptor target and mechanism, read a Certificate of Analysis (CoA) and identify what each assay does and does not establish, and place peptide study data in the correct evidence tier before drawing conclusions. That boundary matters when comparing suppliers on like-for-like criteria [2].

It is written for laboratory researchers and prospective distributors who need precise, consistent language before evaluating research material or interpreting supplier documentation. No human-use guidance appears on this page; all terminology is framed for research purposes only.

This glossary is organised by theme rather than alphabetically, because the terms cluster by function: compound and receptor classes, analytical and batch-document language, product-format and handling vocabulary, and evidence and study-design concepts. Each section stands alone for quick reference; reading them in sequence builds a complete working vocabulary.

Where a term has a deeper dedicated page covering mechanism, receptor profile or analytical method in full, an internal link points there directly. The glossary defines; the linked pages explain. Readers who need to match documentation to physical material should follow those links rather than treating a one-sentence definition as a complete protocol guide.

All definitions follow IUPAC, pharmacopoeial or major regulatory sources where those exist [2]. Where supplier-specific claims appear, they are labelled as such and separated from independent evidence.

Last reviewed: May 2026.

Peptide Testing: What Each Assay Tells You

Each assay on a CoA answers a specific, bounded question. No single test establishes the full quality picture of a batch.

A CoA is a batch-specific document reporting analytical findings for a named lot. A complete CoA typically includes product name, molecular formula, batch or lot number, test dates, high-performance liquid chromatography (HPLC) purity percentage, peptide content against label claim (typically 95–105%), mass spectrometry data (observed versus theoretical molecular weight), endotoxin results, ICP-MS heavy-metal contaminants and, where performed, residual solvents and water content [2].

HPLC separates sample components through a column and detects them, most often by UV absorbance. Purity is expressed as the percentage of integrated area under the main peak versus total peak area, which reflects relative chromatographic purity rather than absolute mass fraction [3]. For a full explanation of what that distinction means in practice, see how HPLC purity is interpreted.

LC-MS (liquid chromatography–mass spectrometry) couples chromatographic separation with mass spectrometric detection. It confirms that the compound’s observed mass matches the theoretical mass within instrument-dependent tolerance, making it an identity check rather than a purity measurement [3].

Endotoxin testing methods such as Limulus Amebocyte Lysate (LAL) and recombinant Factor C (rFC) align with European Pharmacopoeia chapter 2.6.14 [1]. Results are reported in endotoxin units per milligram or per millilitre.

Acceptance criteria belong in specific standard operating procedures (SOPs) or regulatory texts rather than in a general glossary, so no universal thresholds are asserted here [2].

To match a CoA to a physical batch, follow the process described in how to verify a CoA against a batch.

Placing Data in the Correct Evidence Tier

Researchers interpreting peptide literature must place data in its correct evidence tier before drawing conclusions about a compound’s properties. The same result carries different weight depending on where in the research hierarchy it sits.

In vitro describes experiments conducted in a controlled environment outside a living organism, such as cell cultures, receptor-binding assays and enzyme inhibition tests. Results establish mechanism hypotheses but do not predict in-vivo behaviour.

In vivo describes experiments conducted within a living organism, typically a rodent model at preclinical stage. In-vivo data provides pharmacokinetic and pharmacodynamic information but does not translate directly to human outcomes.

Preclinical covers both in-vitro and in-vivo work conducted before human trials. A compound with preclinical data only has not been tested in humans in a controlled setting.

Clinical refers to studies involving human participants. Phase I trials assess safety and pharmacokinetics in small groups; Phase II trials explore efficacy signals; Phase III trials are large randomised controlled trials (RCTs) designed to confirm efficacy and monitor adverse events.

RCT is a study design where participants are allocated to treatment or control groups by chance, minimising selection bias. A double-blind RCT means neither participants nor investigators know the assigned treatment during the study period [5].

Mechanism of action describes the specific biochemical interaction through which a compound produces an effect, such as receptor binding, enzyme inhibition or signal transduction pathway activation. Stating a mechanism does not imply clinical efficacy.

Primary endpoint is the pre-specified outcome a trial is powered to detect, for example, percentage weight loss or HbA1c change at a defined time point. Secondary endpoints are additional outcomes measured but not the basis for the trial’s power calculation. Interpreting a compound’s research profile requires knowing which endpoints were primary and which were exploratory, because secondary and exploratory findings carry less inferential weight.

In-vitro receptor affinity data does not establish in-vivo potency; animal-model results do not confirm human pharmacology; and a single trial does not establish a compound class’s full profile [5].

To apply this vocabulary to specific batch documents, the next step is how to verify a CoA against a batch, a structured process for matching analytical data to physical research material.